Related Experiment Video
Updated: Sep 26, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Genomic landscape of sporadic pediatric differentiated thyroid cancers: a systematic review and meta-analysis
Swayamjeet Satapathy1, Chandrasekhar Bal1
1Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Insights
Fusion oncogenes drive most sporadic paediatric differentiated thyroid cancers (DTCs). While RET rearrangement is most common, BRAF mutations also play a significant role in childhood DTCs.
Area of Science:
- Oncology
- Genetics
- Paediatric Medicine
Background:
- Paediatric differentiated thyroid cancers (DTCs) exhibit distinct clinicopathological features and outcomes compared to adult cases.
- Understanding the genetic landscape of sporadic paediatric DTCs is crucial for elucidating their unique pathogenesis.
Purpose of the Study:
- To systematically review and perform a meta-analysis on the prevalence of genetic alterations in sporadic paediatric DTCs.
- To identify the key molecular drivers contributing to the development of childhood thyroid cancer.
Main Methods:
- Adherence to Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines.
- Comprehensive literature search of PubMed and Embase databases up to October 15, 2021.
- Random-effects model meta-analysis to determine pooled prevalence and 95% confidence intervals (CIs) for genetic alterations.
Main Results:
- Analysis of 33 studies involving 1,380 paediatric patients.
- RET rearrangement (24.4%) and BRAF point mutation (21.2%) were the most prevalent genetic alterations.
- Other significant alterations included NTRK rearrangement (13.5%) and DICER1 mutation (12.5%), while RAS and TERT mutations were less common.
Conclusions:
- Fusion oncogenes are the primary drivers of sporadic paediatric DTCs, explaining their distinct clinical behavior.
- BRAF point mutations, though less frequent than in adults, remain a critical factor in paediatric DTC pathogenesis.
Objectives:
Differentiated thyroid cancers (DTCs) in the paediatric population differ from that of their adult counterparts in terms of clinicopathological characteristics and treatment outcomes. This systematic review and meta-analysis was conducted to comprehensively evaluate the prevalence of various genetic alterations underlying the pathogenesis of sporadic paediatric DTCs.
Methods:
This study followed the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. Systematic searches were made on the PubMed and Embase databases using relevant keywords, and articles published until October 15, 2021 were selected. Data on the prevalence of various genetic alterations were extracted from the individual articles. Random-effects model was employed for meta-analysis to generate pooled estimates and their 95% confidence intervals (95% CIs).
Results:
Thirty-three articles comprising 1,380 paediatric patients were included. RET rearrangement (pooled prevalence: 24.4%, 95% CI: 19.1-30.1) was observed to be the most common genetic alteration in sporadic paediatric DTCs, closely followed by BRAF point mutation (pooled prevalence: 21.2%, 95% CI: 17.2-25.5). Other common alterations included: NTRK rearrangement (pooled prevalence: 13.5%, 95% CI: 9.5-17.9) and DICER1 mutation (pooled prevalence: 12.5%, 95% CI: 3.6-25.7). RAS and TERT mutations were observed to be relatively uncommon (pooled prevalence: 5.7%, 95% CI: 2.9-9.3, and 2.2%, 95% CI: 0.4-5.5, respectively). There was no evidence of publication bias.
Conclusions:
Fusion oncogenes are noted to be the major oncogenic drivers in sporadic paediatric DTCs and underlie their unique behaviour. However, despite the relatively lower frequency of BRAF point mutation compared to adults, it remains a major player in childhood DTCs.
More Related Videos
03:55Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023